Product Description
ASX-100 is the first particle-based therapeutic from the PANTHER platform. A microsphere about the same size as a bacteria, ASX-100 is recognized by innate immune cells in the body as a foreign invader and eaten by the cells. (Sourced from: https://www.asalyxabio.com/about-1)
Mechanisms of Action: Immunomodulator
Novel Mechanism: No
Modality: Unknown
Route of Administration: N/A
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Asalyxa Bio
Company Location: Western America
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 1: COVID-19
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
09/23/2025 |
News Article |
NEXTDC Receives Frost & Sullivan's 2025 Australian Competitive Strategy Leadership Recognition in the Data Center Services Industry |
|
11/12/2024 |
News Article |
Light & Wonder, Inc. Reports Third Quarter 2024 Results |
|
06/24/2024 |
News Article |
Paladin Energy to acquire Fission Uranium creating a clean energy leader |
|
01/24/2024 |
News Article |
Board and Executive Update, Ken Brinsden to Transition to Quebec Based CEO / President |
|
10/06/2022 |
PubMed |
Why Is the Australian Health Sector So Far behind in Practising Climate-Related Disclosures? |
|
02/01/2022 |
PubMed |
Potential protective effect of astaxanthin on ovary ischemia-reperfusion injury. |